Donate
Australian & New Zealand Childrens Haematology/Oncology Group

ANZCHOG Children’s Cancer Clinical Trials Repository

Study Title
Phase 2 Study of Blinatumomab (NSC# 765986, IND# 125462) in Combination with Nivolumab (NSC# 748726, IND# 125462), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged ≥1 to <31 Years Old with First Relapse
Protocol ID
AALL1821
Disease (Sub Disease)
Leukaemia (ALL)
Diagnosis Stage
Relapse
Location
WA
Sponsor
National Cancer Institute (NCI)
Trial Status
Open
Sites
Perth Children's Hospital
Study Type
Treatment
Phase
Phase 2
Age Eligibility
1 Year to 31 Years
International registry ID's
NCT04546399
Back to Registry
Study Title Phase 2 Study of Blinatumomab (NSC# 765986 IND# 125462) in Combination with Nivolumab (NSC# 748726 IND# 125462) a Checkpoint Inhibitor of PD-1 in B-ALL Patients Aged ≥1 to <31 Years Old with First Relapse
Protocol ID AALL1821
Disease (Sub Disease) Leukaemia (ALL)
Diagnosis Stage Relapse
Location WA
Sponsor National Cancer Institute (NCI)
Links https://clinicaltrials.gov/ct2/show/NCT04546399
Trial Status Open
Trial Open Date 04/12/2020
Sites Perth Children's Hospital
Study Type Treatment
Phase Phase 2
Age Eligibility 1 Year to 31 Years
International registry ID's NCT04546399